Education
About Us
Working with TipRanks
Follow Us
Palisade Bio (PALI)
NASDAQ:PALI
PALI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $5.52
Previous CloseN/A
Volume307.14K
Average Volume (3M)276.94K
Market Cap
$3.53M
Enterprise ValueN/A
Total Cash (Recent Filing)$9.82M
Total Debt (Recent Filing)$169.00K
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding4,795,646
10 Day Avg. Volume643,261
30 Day Avg. Volume276,935
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-0.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Palisade Bio News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPALI-2108 is being developed as an oral PDE4 inhibitor for ulcerative colitis, a novel approach as no PDE4 inhibitor has been previously approved for this condition.
Market OpportunityThe global inflammatory bowel disease market is estimated at over $20 billion, presenting a significant market opportunity for PALI-2108 if successful.
Safety And TolerancePositive preliminary safety results from Phase 1 study indicate that PALI-2108 was well-tolerated with no treatment-related adverse events or serious adverse events.
Bears Say
Financial StrategyThe analyst's recommendation includes a lower 12-month price target due to expected dilution from future financing needs.
Financing NeedsPalisade Bio will require another financing following the data, which may be more dilutive given the current market dynamics.
Options Prices
Currently, No data available
---
Ownership Overview
0.46% Insiders
0.30% Mutual Funds
3.63% Other Institutional Investors
95.51% Public Companies and
Individual Investors
PALI FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was $0.60 and its highest was $5.52 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is $3.53M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s upcoming earnings report date is Aug 19, 2025 which is in 89 days.
How were Palisade Bio’s earnings last quarter?
Palisade Bio released its earnings results on May 09, 2025. The company reported -$0.465 earnings per share for the quarter, beating the consensus estimate of -$0.473 by $0.008.
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 4,795,646 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Palisade Bio reported an EPS of -$0.465 in its last earnings report, beating expectations of -$0.473. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in PALI
Company Description
Palisade Bio
Palisade Bio (PALI) is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company's core product candidates are designed to address unmet medical needs in the fields of gastrointestinal health, specifically targeting conditions such as inflammatory bowel disease (IBD) and postoperative digestive complications. Utilizing its proprietary technology, Palisade Bio aims to create innovative treatments that improve patient outcomes and quality of life.
PALI Stock 12 Month Forecast
Average Price Target
$2.00
▲( 163.16% Upside)